Plasma kallikrein binding proteins

Abstract

Plasma kallikrein binding proteins and methods of using such proteins are described.

1 .- 24 . (canceled) 
     
     
         25 . An isolated monoclonal antibody, which binds human plasma kallikrein (pKal), wherein the antibody
 (i) competes with epi-Kal 2 for binding to the human pKal,   (ii) competes with AEBSF for binding to the human pKal, and/or   (iii) decreases the catalytic activity of the human pKal as compared to the catalytic activity of the human pKal in the absence of the monoclonal antibody and under the same conditions.   
     
     
         26 . The isolated monoclonal antibody of  claim 25 , wherein the monoclonal antibody binds human plasma prekallikrein less effectively relative to the human pKal by a factor of at least 10 fold. 
     
     
         27 . The isolated monoclonal antibody of  claim 26 , which binds human plasma prekallikrein less effectively relative to the human pKal by a factor of at least 100 fold. 
     
     
         28 . The isolated monoclonal antibody of  claim 27 , which binds human plasma prekallikrein less effectively relative to the human pKal by a factor of at least 1000 fold. 
     
     
         29 . The isolated monoclonal antibody of  claim 25 , wherein the monoclonal antibody decreases the production of Factor XIIa or bradykinin by at least 50% as compared to the production of Factor XIIa or bradykinin in the absence of the monoclonal antibody and under the same conditions. 
     
     
         30 . The isolated monoclonal antibody of  claim 29 , wherein the monoclonal antibody decreases the production of Factor XIIa or bradykinin by at least 75% as compared to the production of Factor XIIa or bradykinin in the absence of the monoclonal antibody and under the same conditions. 
     
     
         31 . The isolated monoclonal antibody of  claim 30 , wherein the monoclonal antibody decreases the production of Factor XIIa or bradykinin by at least 90% as compared to the production of Factor XIIa or bradykinin in the absence of the monoclonal antibody and under the same conditions. 
     
     
         32 . The isolated monoclonal antibody of  claim 25 , which is a human antibody. 
     
     
         33 . The isolated monoclonal antibody of  claim 25 , which is an IgG molecule. 
     
     
         34 . The isolated monoclonal antibody of  claim 33 , which is an IgG1 molecule. 
     
     
         35 . The isolated monoclonal antibody of  claim 32 , which is a germlined antibody. 
     
     
         36 . The isolated monoclonal antibody of  claim 25 , which is substantially a full-length antibody. 
     
     
         37 . The isolated monoclonal antibody of  claim 25 , which comprises an antigen-binding fragment of a full-length antibody. 
     
     
         38 . The isolated monoclonal antibody of  claim 25 , which comprises a heavy chain variable region and a light chain variable region. 
     
     
         39 . A pharmaceutical composition, comprising the monoclonal antibody of  claim 25  and a pharmaceutically acceptable carrier. 
     
     
         40 . A method for treating hereditary angioedema, comprising administering to a subject in need thereof an effective amount of the monoclonal antibody of  claim 25 .